Skip to main content
. 2016 Jul 21;11(7):e0159693. doi: 10.1371/journal.pone.0159693

Fig 2. Validation and evaluation of plasma miR-223 as a biomarker of oral cancer.

Fig 2

(A) The relative level of miR-223 expression in plasma from patients with GSCC and controls: let7a was used for normalization; *, P < 0.05. (B) Receiver operating characteristics (ROC) curve analysis using plasma miR-223 to differentiate oral cancer.